|Day's Range||47.61 - 49.32|
|52 Week Range||41.38 - 53.50|
|PE Ratio (TTM)||23.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
Back in January, Bedford-based Anika Therapeutics disclosed in a one-sentence federal filing that one of its top executives, chief medical officer Stephen Mascioli, had left the company after less than a year on the job. Anika (ANIK) said Friday that it had agreed to pay Mascioli $350,000 for “alleged damages and attorneys’ fees,” including $250,000 for alleged lost wages. While the filing did not disclose the nature of Mascioli’s allegations, it said that he had agreed not to pursue any legal action against Anika, including potential claims for age discrimination and retaliation.
Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.